MPM BioImpact’s Cymabay Therapeutics CBAY Stock Holding History

MPM BioImpact’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-611,181	Closed	-$14.4M	–	42
2023 Q4	$14.4M	Buy	611,181 +411	+0.1%	+$7.32K	3.38%	11
2023 Q3	$9.11M	Buy	+610,770	New	+$8.1M	2.43%	15

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MPM BioImpact's CBAY Position: Q1 2024 in Review

MPM BioImpact sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 611,181 shares — an estimated $14.4M sold.

MPM BioImpact first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $14.4M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

MPM BioImpact reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
MPM BioImpact sold 611,181 Cymabay Therapeutics shares in Q1 2024, an estimated $14.4M.
MPM BioImpact first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
MPM BioImpact's Cymabay Therapeutics position peaked at $14.4M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.